ОСОБЕННОСТИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ ВИРУСНОГО ГЕПАТИТА С У ДЕТЕЙ С РАЗЛИЧНЫМИ ВАРИАНТАМИ ПОЛИМОРФИЗМА ГЕНА IL28B
Аннотация
Ключевые слова
Об авторах
И. А. МатинянРоссия
Т. Б. Сенцова
Россия
И. В. Ворожко
Россия
О. О. Черняк
Россия
Т. В. Строкова
Россия
М. М. Гаппаров
Россия
Список литературы
1. Suzuki M, Tajiri H. Peginterferon Therapy in Children with Chronic Hepatitis C: A Nationwide, Multi-center Study in Japan, 2004-2013. J Pediatr Gastroenterol Nutr. 2016 Jan 27.
2. Robinson MW, Hughes J. Tracking TCRβ sequence clonotype expansions during antiviral therapy using high-throughput sequencing of the hypervariable region. Front Immunol. 2016 Apr 5;7:131.
3. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105-1109.
4. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. [PubMed].
5. Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol.2011;9:344-350.
6. Rauch A., Kutalik Z., Descombes P. et al. Genetic variation in IL28 B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010. Vol. 138, № 4. P. 1338-1345
7. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
8. Gale M, Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature. 2005;436:939-945.
9. Симанкова Т. В., Гармаш И. В., Аришева О. С. и др. Генетический полиморфизм гена ИЛ-28B как предиктор успеха ПВТ хронического гепатита С. Клиническая фармакология и терапия. 2012. Т. 21. No 1. С. 1-6.
10. Moghaddam A., Melum E., Reinton N. et al. Hepatology. 2011. V. 53. P. 746-754.
11. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
12. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140:346-355.
13. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
14. David L. Thomas, M. D. Predicting the Response to the Treatment of Hepatitis C Virus Infection. Clinical Liver Disease, Vol. 1, No. 2, April 2012: 46-48.
15. A. J. Thompson. Genetic factors and hepatitis C virus infection. Gastroenterology. 2012. Vol. 142. P. 1335-1339.
16. Stevan A. Gonzalez, Emmet B. Keeffe. IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y). 2011 Jun; 7 (6): 366-373.
Рецензия
Для цитирования:
Матинян И.А., Сенцова Т.Б., Ворожко И.В., Черняк О.О., Строкова Т.В., Гаппаров М.М. ОСОБЕННОСТИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ ВИРУСНОГО ГЕПАТИТА С У ДЕТЕЙ С РАЗЛИЧНЫМИ ВАРИАНТАМИ ПОЛИМОРФИЗМА ГЕНА IL28B. Экспериментальная и клиническая гастроэнтерология. 2016;(7):52-55.
For citation:
Matinyan I.A., Sentsova T.B., Vorozhko I.V., Chernyak O.O., Strokova T.V., Gapparov M.M. THE CLINICAL COURSE OF HEPATITIS C IN CHILDREN WITH DIFFERENT VARIANTS OF THE GENE POLYMORPHISM IL28B. Experimental and Clinical Gastroenterology. 2016;(7):52-55. (In Russ.)